Long-term symptoms after SARS-CoV-2 infection in a cohort of people living with HIV DOI Creative Commons
Melania Degli Antoni, Giovanni Maifredi,

Samuele Storti

et al.

Infection, Journal Year: 2024, Volume and Issue: unknown

Published: May 3, 2024

Abstract Background Our Hospital in Northern Italy assists 3817 people living with HIV (PLWH) and has faced the impact of COVID-19. Little is known about infection on risk post-COVID-19 conditions (PCCs) onset. We aim to assess incidence PCC PLWH factors associated its occurrence. Methods performed a retrospective, observational study including all > 18 years registered Brescia Health Protection Agency database, assessing SARS-CoV-2 burden, vaccination status, socio-demographic, viro-immunological parameters from February 2020 until May 2022. Persistence self-reported symptoms (clustered into gastrointestinal, respiratory, osteo-muscular, neuro-behavioral symptoms) was evaluated after 3 months by telephone-administered questionnaire. estimated associations between variables outcomes through univariate multivariable logistic models. Results In period, 653 were diagnosed (17.1%). observed 19 (2.9%) reinfections, 71 (10.9%) hospitalizations, (0.5%) deaths. interviewed 510/653 (78%), 178 (PCCs prevalence 34.9%; CI 95% 30.7–39.2) reported persistent symptoms. Asthenia/fatigue most symptom (60/178), followed muscular pain (54/178). multivariate regression model, there lower PCCs males respect females (adjusted OR = 0.64; 0.99–3.66), while hospitalization during acute an increased 1.9; 0.99–3.66). Notably, no variable modified Conclusions highlights substantial among PLWH, three post-SARS-CoV-2 infection, independent features or status.

Language: Английский

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan DOI Creative Commons

Mitsuhiro Nagano,

Kazumasa Kamei,

Hiroyuki Matsuda

et al.

Expert Review of Vaccines, Journal Year: 2024, Volume and Issue: 23(1), P. 349 - 361

Published: Feb. 27, 2024

Background The aim of this study was to evaluate the public health and economic impact COVID-19 booster vaccination with BNT162b2 in Japan during an Omicron-dominant period from early 2022.

Language: Английский

Citations

4
Long COVID: current research and future directions DOI Creative Commons
Rongling Zhang,

Xiaoying Gu,

Hui Zhang

et al.

Infectious Diseases & Immunity, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Abstract Long coronavirus disease (COVID) is defined as the continuation or development of new symptoms three months after severe acute respiratory syndrome 2 (SARS-CoV-2) infection, and that last for at least two months, with no other explanation their cause. This includes various clinical manifestations affect multiple organ systems, such complications in respiratory, cardiovascular, neurological, musculoskeletal systems. The most commonly reported include fatigue, cognitive dysfunction, dyspnea, chest pain; however, prevalence severity these vary greatly among individuals. underlying mechanisms long COVID are complex multifaceted, encompassing viral persistence, immune system mitochondrial abnormalities, endothelial impairment, alterations microbiome. Further, has imposed a significant burden on individuals, healthcare economy by impairing an individual’s quality life functional capacity, thereby increasing costs demand care rehabilitation services. review summarizes definition, phenotypes, mechanisms, current treatment advancements highlights specific research directions future investigation.

Language: Английский

Citations

0
Comparative study of stigma and discrimination among vaccinated and non-vaccinated COVID-19 survivors in Bangladesh DOI Creative Commons
Tamanna Rashid, Shamsul Arefin, Mowsume Bhattacharjee

et al.

BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)

Published: March 10, 2025

Abstract This study investigates the stigmatized experiences of vaccinated and non-vaccinated COVID-19 survivors in Bangladesh, emphasizing factors contributing to stigma, lived realities stigmatization, strategies for mitigating discrimination. Employing a qualitative comparative case approach, research draws on interviews with 22 (13 9 vaccinated) conducted during two critical phases pandemic: July–August 2020 October 2022–April 2023. The findings reveal that stigma discrimination were pervasive, stemming from deep-seated fears death infection, exacerbated by public health measures such as lockdowns, announcements, symbolic marking houses red flags. Experiences surrounding testing further intensified influencing how perceived treated others. Notably, reported broader spectrum stigmatizing compared their counterparts, highlighting differential impact vaccination status social experiences. Despite these challenges, identified key alleviating including robust support, strengthened community connectivity, normalized attitudes toward COVID-19, proactive media engagement. As result, this offers valuable insights healthcare professionals policymakers informing development effective pandemic management strategies. Additionally, it enhances our understanding complex interplay between policy, perception, individual shaping pandemic-related discrimination, role support care addressing challenges.

Language: Английский

Citations

0
Factors affecting the impact of COVID-19 vaccination on post COVID-19 conditions among adults: A systematic literature review DOI Creative Commons
Abby E. Rudolph,

Nadine Al Akoury,

Natalija Bogdanenko

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2025, Volume and Issue: 21(1)

Published: March 13, 2025

This systematic literature review summarizes the evidence across 56 publications and pre-prints (January 2020–July 2023) with low-risk of bias based on JBI critical appraisal, that report adjusted estimates for relationship between COVID-19 vaccination Post-COVID-19 Condition (PCC) by timing relative to infection or PCC-onset. Comparisons vaccine effectiveness (aVE) against ≥1 PCC (vs. unvaccinated) study characteristics known impact burden VE other endpoints were possible 31 studies where preceded infection. Seventy-seven percent pre-infection aVE statistically significant (range: 7%–95%). Statistically slightly higher mRNA 14%–84%) than non-mRNA vaccines 16%–38%) ranges before during Omicron overlapped. Our findings suggest SARS-CoV-2 reduces risk regardless type, number doses received, definition, predominant variant, severity acute infections included.

Language: Английский

Citations

0
Wearable data reveals distinct characteristics of individuals with persistent symptoms after a SARS-CoV-2 infection DOI Creative Commons
Katharina Ledebur, Marc Wiedermann, Christian Puta

et al.

npj Digital Medicine, Journal Year: 2025, Volume and Issue: 8(1)

Published: March 19, 2025

Abstract Understanding the factors associated with persistent symptoms after SARS-CoV-2 infection is critical to improving long-term health outcomes. Using a wearable-derived behavioral and physiological dataset ( n = 20,815), we identified individuals characterized by self-reported fatigue shortness of breath infection. Compared symptom-free COVID-19 positive (n 150) negative controls 150), these 50) had higher resting heart rates (mean difference 2.37/1.49 bpm) lower daily step counts 3030/2909 steps fewer), even at least three weeks prior In addition, were significant reduction in mean quality life (WHO-5, EQ-5D), before Here show that may be pre-existing fitness levels or conditions. These findings additionally highlight potential wearable devices track dynamics provide valuable insights into outcomes infectious diseases.

Language: Английский

Citations

0
Identifying risk factors and predicting long COVID in a Spanish cohort DOI Creative Commons
Antonio Guillén-Teruel,

Jose L. Mellina-Andreu,

Gabriel Reina

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: March 28, 2025

Many studies have investigated symptoms, comorbidities, demographic factors, and vaccine effects in relation to long COVID (LC-19) across global populations. However, a number of these shortcomings, such as inadequate LC-19 categorisation, lack sex disaggregation, or narrow focus on certain risk factors like symptoms comorbidities alone. We address gaps by investigating the present during acute phase primary COVID-19 infection among patients with comparing them typical non-Long patients. Additionally, we assess impact vaccination Drawing data from Regional Health System Region Murcia southeastern Spain, our analysis includes comprehensive information clinical hospitalisation records, details over 675126 10 hospitals. calculated age sex-adjusted odds ratios (AOR) identify protective for LC-19. Our findings reveal distinct symptomatology, comorbidity patterns, characteristics versus those COVID-19. Factors age, female (AOR = 1.39, adjusted p < 0.001), chest pain > 1.55, 0.001) hyposmia 1.5, significantly increase developing demonstrates strong effect, vaccinated individuals having markedly lower 0.10, highlighting importance reducing susceptibility. Interestingly, show no significant differences when disaggregated type patient. Vaccination before is most important factor notably decreases likelihood COVID. Particularly, mRNA vaccines offer more protection against than viral vector-based 0.48). developed model predict that incorporates all studied achieving balanced accuracy 73% ROC-AUC 0.80. This available free online calculator, accessible at ( Calculator ).

Language: Английский

Citations

0
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of Post-COVID-19 condition in vulnerable populations DOI Creative Commons
Elisa Gentilotti, Lorenzo Maria Canziani,

Maria Giulia Caponcello

et al.

Clinical Microbiology and Infection, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France DOI Open Access
Amy S. Lee, Benjamin Davido, Ekkehard Beck

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: March 15, 2024

ABSTRACT An economic evaluation was conducted to predict the and clinical burden of vaccinating immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines in Fall 2023 Spring 2024 versus BNT162b2 France. The number symptomatic infections, hospitalizations, deaths, long COVID cases, costs quality-adjusted life (QALYs) estimated using a static decision-analytic model. Predicted vaccine effectiveness (VE) were based on real-world data from prior versions, suggesting higher protection against infection hospitalization vaccines. VE estimates combined incidence probability severe outcomes. Uncertainty surrounding VE, coverage, incidence, mortality rates, QALYs tested sensitivity analyses. is predicted prevent an additional 3,882 357 81 326 cases when compared 230,000 IC individuals. This translates €10.1 million cost-savings societal perspective 645 saved. Results consistent across all analyses most sensitive variations coverage. These findings highlight importance increasing ability induce levels formulations this vulnerable population.

Language: Английский

Citations

3
The effectiveness of the COVID-19 vaccines in the prevention of post-COVID conditions in children and adolescents: a systematic literature review and meta-analysis DOI Creative Commons
Maria Celidonio Gutfreund, Takaaki Kobayashi, Gustavo Yano Callado

et al.

Antimicrobial Stewardship & Healthcare Epidemiology, Journal Year: 2024, Volume and Issue: 4(1)

Published: Jan. 1, 2024

We performed a systematic literature review and meta-analysis on the effectiveness of coronavirus disease 2019 (COVID-19) vaccination against post-COVID conditions (long COVID) in pediatric population.

Language: Английский

Citations

3
Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes DOI Creative Commons
Piotr Rzymski, Jacek Niedziela,

Barbara Poniedziałek

et al.

Virology, Journal Year: 2024, Volume and Issue: 596, P. 110118 - 110118

Published: May 23, 2024

Long COVID (LC) is characterized by persistent symptoms following SARS-CoV-2 infection, with various mechanisms offered to explain its pathogenesis. This study explored whether adaptive humoral anti-SARS-CoV-2 responses differ in LC. Unvaccinated COVID-19 convalescents (n = 200) were enrolled, 21.5% 43) presenting LC three months post-infection. diagnosis was based on symptom(s) and alterations biochemical/clinical markers; phenotypes distinguished: cardiological, pulmonary, psychiatric All significantly decreased seroprevalence of IgG antibodies against nucleocapsid (anti-NP). associated odds testing positive for anti-NP (OR 0.35, 95%CI: 0.16-0.78, p 0.001). Seropositive patients had lower anti-S1 anti-S2 levels than individuals without LC, those pulmonary psychological also revealed anti-RBD concentrations. The results indicate that can be diminished response SARS-CoV-2. potential implication this phenomenon post-acute viral sequelae discussed.

Language: Английский

Citations

3